FDA Inspection
Biogen U.S. CorporationBiogen U.S. Corporation – FDA Inspection, May 4, 2018
Record Details
This FDA Inspection record concerns Biogen U.S. Corporation, with an inspection on May 4, 2018, issued by the Atlanta District Office, covering human drugs.
- Office
- Atlanta District Office
- People
- Ephrem T. Hunde (Issuing Officer)
- Viviana R. Ramirez (Issuing Officer)
View Company Profile
ID · ba6308ee-6cd0-4ad1-896b-43c8bf2c2ca8
Inspection Facts
- Inspection number
- 1052799
- FDA center
- Human Drugs
- Outcome
- Form 483 issued
Other FDA inspections of Biogen U.S. Corporation
4| Date | Classification | Office | Project area |
|---|---|---|---|
| October 17, 2023 | VAI | Center for Biologics Evaluation and Research | Blood and Blood Products |
| August 26, 2022 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| December 10, 2015 | VAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
| April 16, 2015 | NAI | Center for Drug Evaluation and Research | Drug Quality Assurance |
Other documents for Biogen U.S. Corporation
- FDA Inspection 1220500 - 2023-10-17
- FDA Inspection 1178753 - 2022-08-26
- FDA Inspection 951256 - 2015-12-10
- FDA Inspection 922850 - 2015-04-16
Document or profile
One record shows the event. A profile shows the pattern.
Buy this document for the source file and details behind this single event.
Choose full profile access to connect related records, sites, people, citations, and enforcement history in one view.